BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lintuzumab: Development discontinued

Seattle Genetics discontinued development of lintuzumab after data from a double-blind, international Phase IIb trial in 211 previously untreated AML patients >=60 years old showed that the compound plus low-dose cytarabine missed the primary endpoint of significantly improving OS vs. placebo plus cytarabine. The company said it plans to fulfill...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >